alexa Boceprevir.
Microbiology

Microbiology

Journal of Antivirals & Antiretrovirals

Author(s): No authors listed

Abstract Share this page

Abstract Boceprevir (SCH 503034; SCH-503034) is a peptidomimetic NS3/4A serine protease inhibitor, representing a new class of hepatitis C virus (HCV) inhibitors. It is being developed by Merck & Co. as part of a combination therapy regimen for the treatment of HCV infections. In two phase III trials, the HCV RESPOND-2 and HCV SPRINT-2 trials, the primary endpoints were met. Phase III development continues in the US, Europe, and Canada. This review looks at the key development milestones and therapeutic trials of this drug.
This article was published in Drugs R D and referenced in Journal of Antivirals & Antiretrovirals

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords